Chondrogenic and BMP-4 primings confer osteogenesis potential to human cord blood mesenchymal stromal cells delivered with biphasic calcium phosphate ceramics.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 03 2021
Historique:
received: 02 07 2020
accepted: 24 02 2021
entrez: 25 3 2021
pubmed: 26 3 2021
medline: 26 10 2021
Statut: epublish

Résumé

Bone marrow mesenchymal stem/stromal cells (BMSCs) show great promise for bone repair, however they are isolated by an invasive bone marrow harvest and their regenerative potential decreases with age. Conversely, cord blood can be collected non-invasively after birth and contains MSCs (CBMSCs) that can be stored for future use. However, whether CBMSCs can replace BMSCs targeting bone repair is unknown. This study evaluates the in vitro osteogenic potential of unprimed, osteogenically primed, or chondrogenically primed CBMSCs and BMSCs and their in vivo bone forming capacity following ectopic implantation on biphasic calcium phosphate ceramics in nude mice. In vitro, alkaline phosphatase (intracellular, extracellular, and gene expression), and secretion of osteogenic cytokines (osteoprotegerin and osteocalcin) was significantly higher in BMSCs compared with CBMSCs, while CBMSCs demonstrated superior chondrogenic differentiation and secretion of interleukins IL-6 and IL-8. BMSCs yielded significantly more cell engraftment and ectopic bone formation compared to CBMSCs. However, priming of CBMSCs with either chondrogenic or BMP-4 supplements led to bone formation by CBMSCs. This study is the first direct quantification of the bone forming abilities of BMSCs and CBMSCs in vivo and, while revealing the innate superiority of BMSCs for bone repair, it provides avenues to induce osteogenesis by CBMSCs.

Identifiants

pubmed: 33762629
doi: 10.1038/s41598-021-86147-9
pii: 10.1038/s41598-021-86147-9
pmc: PMC7991626
doi:

Substances chimiques

BMP4 protein, human 0
Biomarkers 0
Bone Morphogenetic Protein 4 0
Bone Substitutes 0
Cytokines 0
Hydroxyapatites 0
hydroxyapatite-beta tricalcium phosphate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6751

Références

Stem Cell Reports. 2016 Jun 14;6(6):897-913
pubmed: 27304917
Nat Commun. 2015 Jun 12;6:7443
pubmed: 26068133
J Cell Physiol. 2020 May;235(5):4643-4654
pubmed: 31650536
Tissue Eng. 2001 Apr;7(2):211-28
pubmed: 11304456
EBioMedicine. 2020 Jul;57:102848
pubmed: 32574961
Biomaterials. 2019 Mar;196:100-108
pubmed: 29598897
Stem Cells Int. 2017;2017:3674045
pubmed: 28744314
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
Asian J Transfus Sci. 2010 Jan;4(1):14-24
pubmed: 20376261
Front Bioeng Biotechnol. 2020 Mar 31;8:230
pubmed: 32296687
Stem Cells Transl Med. 2017 Dec;6(12):2160-2172
pubmed: 29052365
Biomaterials. 2014 Dec;35(36):9660-7
pubmed: 25176068
Stem Cells. 2006 May;24(5):1294-301
pubmed: 16410387
Br J Haematol. 2000 Apr;109(1):235-42
pubmed: 10848804
Adv Funct Mater. 2020 Sep 10;30(37):
pubmed: 32952493
Injury. 2020 Apr;51 Suppl 1:S63-S73
pubmed: 32139130
Front Immunol. 2019 Apr 02;10:663
pubmed: 31001270
Front Bioeng Biotechnol. 2015 Jun 02;3:79
pubmed: 26082926
Exp Biol Med (Maywood). 2008 Jul;233(7):901-13
pubmed: 18445775
Front Bioeng Biotechnol. 2020 Feb 12;8:61
pubmed: 32117940
Cells. 2019 Nov 07;8(11):
pubmed: 31703272
Cell Biol Int. 2006 Jul;30(7):569-75
pubmed: 16716607
Sci Rep. 2019 Oct 28;9(1):15420
pubmed: 31659213
Tissue Eng Part A. 2018 Aug;24(15-16):1262-1272
pubmed: 29478385
Tissue Eng Part C Methods. 2016 May;22(5):487-95
pubmed: 27019357
Cell Transplant. 2016;25(8):1501-14
pubmed: 26850072
Tissue Eng Part A. 2010 Aug;16(8):2475-83
pubmed: 20214449
Stem Cells Int. 2018 Sep 5;2018:4258613
pubmed: 30254682
Tissue Eng Part C Methods. 2014 Mar;20(3):239-51
pubmed: 23845029
Stem Cell Res. 2013 Nov;11(3):1393-406
pubmed: 24140198
Exp Hematol. 2005 Nov;33(11):1402-16
pubmed: 16263424
Tissue Eng. 2005 Sep-Oct;11(9-10):1407-20
pubmed: 16259596
BMC Musculoskelet Disord. 2011 Jan 31;12:31
pubmed: 21281488
Sci Rep. 2017 Jul 18;7(1):5777
pubmed: 28720829
Stem Cells Transl Med. 2016 Aug;5(8):1090-7
pubmed: 27334490
Tissue Eng Part A. 2016 Mar;22(5-6):556-67
pubmed: 26896424
J Vet Sci. 2006 Dec;7(4):343-8
pubmed: 17106225
Tissue Eng Part A. 2009 Aug;15(8):2203-12
pubmed: 19265473
Mol Cell Biol. 2004 Oct;24(20):9248-61
pubmed: 15456894
Stem Cell Res Ther. 2014 Oct 13;5(5):114
pubmed: 25311054
Sci Transl Med. 2019 May 15;11(492):
pubmed: 31092696
Stem Cell Res Ther. 2018 Aug 9;9(1):213
pubmed: 30092840
Stem Cells. 2006 Mar;24(3):679-85
pubmed: 16179428
Tissue Eng Part A. 2010 Mar;16(3):971-82
pubmed: 19839720
Genes Cells. 2001 Oct;6(10):851-6
pubmed: 11683913
Stem Cells Dev. 2015 Jan 1;24(1):104-14
pubmed: 25046283
Int J Biochem Cell Biol. 2013 Nov;45(11):2456-66
pubmed: 23942228

Auteurs

Meadhbh Á Brennan (MÁ)

Inserm, UMR 1238, PHY-OS Laboratory, Bone Sarcomas and Remodelling of Calcified Tissues, Faculty of Medicine, University of Nantes, Nantes, France.
National University of Ireland (NUIG), Galway, Ireland.

Mario Barilani (M)

Laboratory of Regenerative Medicine-Cell Factory, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Francesco Rusconi (F)

Laboratory of Regenerative Medicine-Cell Factory, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Julien de Lima (J)

Inserm, UMR 1238, PHY-OS Laboratory, Bone Sarcomas and Remodelling of Calcified Tissues, Faculty of Medicine, University of Nantes, Nantes, France.

Luciano Vidal (L)

Inserm, UMR 1238, PHY-OS Laboratory, Bone Sarcomas and Remodelling of Calcified Tissues, Faculty of Medicine, University of Nantes, Nantes, France.
Rapid Manufacturing Platform, GEM Laboratory, Centrale Nantes, Nantes, France.

Cristiana Lavazza (C)

Laboratory of Regenerative Medicine-Cell Factory, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Lorenza Lazzari (L)

Laboratory of Regenerative Medicine-Cell Factory, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Rosaria Giordano (R)

Laboratory of Regenerative Medicine-Cell Factory, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Pierre Layrolle (P)

Inserm, UMR 1238, PHY-OS Laboratory, Bone Sarcomas and Remodelling of Calcified Tissues, Faculty of Medicine, University of Nantes, Nantes, France. pierre.layrolle@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH